FTC opens investigation into largest PBMs' anticompetitive practices

Beth Snyder Bulik

Senior Editor

The Federal Trade Commission is turning up the heat on the drug industry’s middlemen, launching an investigation into pharmacy benefit manager practices and the effect …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FTC opens investigation into largest PBMs' anticompetitive practices

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

FTC opens in­ves­ti­ga­tion in­to largest PBM­s' an­ti­com­pet­i­tive prac­tices

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FTC opens investigation into largest PBMs' anticompetitive practices